Date: 2014-09-25
Type of information: Services contract
Compound: companion diagnostics for novel, genetically-targeted cancer medicines
Company: Horizon Discovery (UK) undisclosed major global diagnostic development company and US biopharmaceutical company
Therapeutic area: Cancer - Oncology
Type agreement: services development
Action mechanism:
Disease:
Details: * On 25 September 2014, Horizon Discovery Group, a provider of research tools to support translational genomics and the development of personalized medicines, announces that its business unit Horizon Diagnostics has signed a Master Services Agreement with a major global diagnostic development company and a US biopharmaceutical company to support the development of companion diagnostics for novel, genetically-targeted cancer medicines. The first project covered by the agreement requires the generation of genetically defined cell lines and related gDNA and FFPE standards by Horizon Diagnostics for a total consideration of approximately $1.2 million. A large proportion of the revenue from the deal will be recognized by Horizon in the second half of 2014. The commercial terms of the deal are currently non-exclusive, however they include an option of exclusivity on terms to be negotiated in the future.
Financial terms:
Latest news:
